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Abstract
Background:  The purpose of the present study was to continue the investigation of the
membrane transport mechanisms of 20-(S)-camptothecin (CPT) in order to understand the
possible role of membrane transporters on its oral bioavailability and disposition.
Methods: The intestinal transport kinetics of CPT were characterized using Caco-2 cells, MDCKII
wild-type cells and MDCKII cells transfected with human P-glycoprotein (PGP) (ABCB1) or human
multidrug resistance protein 2 (MRP2) (ABCC2). The effects of drug concentration, inhibitors and
temperature on CPT directional permeability were determined.
Results: The absorptive (apical to basolateral) and secretory (basolateral to apical) permeabilities
of CPT were found to be saturable. Reduced secretory CPT permeabilities with decreasing
temperatures suggests the involvement of an active, transporter-mediated secretory pathway. In
the presence of etoposide, the CPT secretory permeability decreased 25.6%. However, inhibition
was greater in the presence of PGP and of the breast cancer resistant protein inhibitor, GF120918
(52.5%). The involvement of additional secretory transporters was suggested since the basolateral
to apical permeability of CPT was not further reduced in the presence of increasing concentrations
of GF120918. To investigate the involvement of specific apically-located secretory membrane
transporters, CPT transport studies were conducted using MDCKII/PGP cells and MDCKII/MRP2
cells. CPT carrier-mediated permeability was approximately twofold greater in MDCKII/PGP cells
and MDCKII/MRP2 cells than in MDCKII/wild-type cells, while the apparent Km values were
comparable in all three cell lines. The efflux ratio of CPT in MDCKII/PGP in the presence of 0.2 µM
GF120918 was not completely reversed (3.36 to 1.49). However, the decrease in the efflux ratio
of CPT in MDCKII/MRP2 cells (2.31 to 1.03) suggests that CPT efflux was completely inhibited by
MK571, a potent inhibitor of the Multidrug Resistance Protein transporter family.
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Conclusions: The current results provide evidence that PGP and MRP2 mediate the secretory
transport of CPT in vitro. However, the involvement of other transporters cannot be ruled out
based on these studies. Since these transporters are expressed in the intestine, liver and kidney
variations in their expression levels and/or regulation may be responsible for the erratic oral
absorption and biliary excretion of CPT observed in human subjects.
Background
20-(S)-camptothecin (CPT) is a cytotoxic alkaloid
extracted from the Chinese tree Camptotheca acuminata. It
has been shown to exhibit potent antitumor activity in
several experimental tumor types [1]. In the 1970s, how-
ever, due to the poor aqueous solubility of CPT (2.5 µg/
ml), the water-soluble sodium salt NSC100880 was for-
mulated for use in phase I and phase II clinical trials. The
results of these trials were disappointing, demonstrating
minimal antitumor activity with severe and unpredictable
toxicity. This led to the discontinuation of the clinical
studies [2]. Failure of the early CPT trials was attributed to
the conversion of the pharmacologically active CPT-lac-
tone form to the toxic and inactive carboxylate form in the
dosage that was administered to patients [3]. Interest in
CPT was revived in the late 1980s for several reasons: the
identification of the enzyme topoisomerase I as the major
cellular target of CPT [4], the discovery of overexpressed
levels of topoisomerase I in tumor cells relative to normal
cells [5], the elucidation of the structure–activity relation-
ship of CPT [3], and the potency of several CPT analogs in
various malignant cell lines. Two water-soluble deriva-
tives of CPT, irinotecan (CPT-11) and topotecan (TPT),
have received approval for use in the USA from the Food
and Drug Administration. Various CPT prodrugs are cur-
rently being evaluated in clinical trials.
Camptothecins are cell cycle specific, demonstrating
greatest activity in the S-phase. They reversibly stabilize
the cleavable complex formed between topoisomerase I
and DNA, thus arresting single-strand DNA replication
and causing breaks in the double strands. Prolonged or
repetitive exposure to these drugs is therefore necessary to
increase cell killing since the S-phase is a short phase of
the cell cycle. Preclinical and clinical studies have shown
that prolonged exposure to CPT and its analogs, through
either continuous intravenous infusion or oral adminis-
tration, results in optimal therapeutic activity [6-8]. The
oral delivery route is preferable due to patient compliance
considerations, decreased vascular access complications,
convenience and low cost. However, clinical evaluation of
orally administered CPT indicated variability in the area
under the curve (164%) and the bioavailability (10-fold)
[9]. Physicochemical factors such as solubility and disso-
lution as well as physiological factors (e.g. intestinal
absorptive and secretory permeability and first-pass
metabolism) are thought to be responsible for variations
in the rate and extent of absorption. For CPT and its ana-
logs, however, physicochemical factors are less likely to
play a crucial role since erratic bioavailability was also
observed with both polar (CPT-11 and TPT) and nonpolar
(9-nitrocamptothecin) analogs [10-12]. The observed var-
iability in the area under the curve for CPT-11 and TPT
was reported as 50% and 41%, respectively, while peak
blood concentrations ranged from 26 ng/ml to 517 ng/ml
for 9-nitrocamptothecin. In addition, CPT undergoes sub-
stantial biliary excretion resulting in micellar solubiliza-
tion and complete dissolution of the drug, thus
overcoming the solubility limitations [13].
Due to the expression of various secretory membrane
transporters (e.g. breast cancer resistant protein [BCRP],
human Multidrug Resistance Protein [MRP1–MRP3], P-
glycoprotein [PGP]) in the intestine, we postulated that
CPT might be a substrate for these efflux transporters. We
have therefore initially focused on two well-studied mem-
brane transporters, PGP (ABCB1) and MRP2 (ABCC2).
Variations in the intestinal expression and activity of PGP
and/or MRP2 may contribute to the erratic bioavailability
observed in human subjects. It is also possible that MRP1,
MRP3 and BCRP play a role in CPT transport; however,
given the lack of specific inhibitors, this remains to be
determined. For example, BCRP, a recently identified
member of the family of ATP-dependent drug efflux pro-
teins, is a half-transporter expressed in the placenta, the
canalicular membranes of the liver, the apical region of
the epithelium of the small and large intestine and the
ovaries. It appears to play a protective and excretory role
similar to many other ABC transporters and thus may also
contribute to the poor oral bioavailability of the CPTs.
Several studies have demonstrated that BCRP is an effi-
cient transporter of the CPT analog TPT [14-16]. It also
mediates the transport of 9-aminocamptothecin [16].
However, there is no conclusive evidence to date of
whether CPT is a substrate for BCRP. Studies are presently
being conducted in our laboratory to confirm the role of
BCRP in CPT absorption and also to identify other trans-
porters that may be responsible for the low and erratic
bioavailability of this drug.
To further elucidate the mechanisms of CPT uptake and
disposition, CPT transport kinetics were investigated
using Caco-2 cells, a cell model commonly used as a
human enterocyte surrogate, and in MDCK II cellsBMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/16
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overexpressing human transporters (MDCK II/wild-type
[wt] cells, MDCK II/PGP cells, and MDCK II/MRP2 cells)
in order to study CPT interactions with individual
transporters.
Methods
Materials
Camptothecin and etoposide were purchased from Sigma
(St Louis, MO, USA) and [3H]CPT was purchased from
Moravek Biochemicals (La Brea, CA, USA). Dr Polli kindly
donated GF120198 (GlaxoSmithKline Inc., Research Tri-
angle Park, NC, USA), and MK571 was provided by Dr
Koch (Merck Co. Inc., Rahway, NJ, USA). PGP and MRP2
antibodies (mAb) C219 and MRP2 H-17 were obtained
from Signet Laboratories (Dedham, MA, USA). All other
materials were purchased from Fisher (Fair Lawn, NJ,
USA) or Sigma and were used as received.
Cell culture
Caco-2 cells were obtained from the American Type Cul-
ture Collection (Rockville, MD, USA) and were frozen at -
80°C. Four weeks prior to the experiment, cells from pas-
sage number 20 were cultured in an atmosphere of 95%
air and 5% CO2 at 37°C in Dulbecco's Modified Eagle's
medium supplemented with 10% fetal bovine serum, 1%
nonessential amino acids, and 2% penicillin-streptomy-
cin. After harvesting at 90% confluency, the cells were
seeded on Snapwell® polycarbonate filter inserts (Corning
Costar Corporation, Cambridge, MA, USA) at a density of
45,000 cells/cm2 and were grown for 21 days. MDCK II/wt
cells, MDCK II/PGP cells and MDCK II/MRP2 cells were
provided by Dr Borst (The Netherlands Cancer Institute,
Amsterdam, The Netherlands) and frozen at -80°C. Four
weeks prior to the experiment, cells from passage number
10 were cultured in a similar manner to that described for
the Caco-2 cells. The cells were harvested at 90% conflu-
ency, and were seeded onto Transwell® polycarbonate fil-
ter inserts (Corning Costar Corporation) at a density of
67,000 cells/cm2 and were grown for 3 days.
Diffusion studies
Drug transport across Caco-2 cells was conducted in side-
by-side diffusion chambers (Harvard Apparatus Inc., Hol-
liston, MA, USA). The chambers were prewarmed to 37°C
prior to mounting the Snapwell polycarbonate filter
inserts with a monolayer of fully differentiated Caco-2
cells. The donor (apical [AP]) and the receptor (basola-
teral [BL]) compartments were filled with the appropriate
buffers. The donor buffer was MES Ringer's buffer (pH
6.5) and the receptor buffer was Ringer's glucose buffer
(pH 7.4), 290 mOsm/kg. To minimize the effect of the
aqueous boundary layer, the fluid in the chambers was
circulated using a gas lift mechanism with 5% CO2 and
95% O2 at a flow rate of 10 ml/min. Drug transport across
MDCKII cell monolayers was conducted in Transwell
plates, which were placed on an orbital shaker (40 rpm)
to reduce the influence of the aqueous boundary layer.
Both the donor and receptor compartments were filled
with Hank's Balanced Salts Buffer (pH 7.4, 10 mM
Hepes). The drug solution (spiked with a trace amount of
[3H]CPT to achieve a specific activity of 0.2 µCi/ml) was
placed in the donor chamber. Samples were removed
from the receptor chamber at 30, 45, 60, 75, 90, 105 min,
followed by immediate replacement of an equivalent vol-
ume of prewarmed buffer. The integrity of the cell monol-
ayer was evaluated before and after the experiment by
measuring the transepithelial electrical resistance and
[14C]mannitol transport. Transepithelial electrical resist-
ance measurements of 300–350 Ωcm2 and mannitol per-
meability values < 1 × 10-6  cm/s indicated that the
monolayer integrity was not compromised.
Various kinetic studies were conducted to elucidate the
transport pathways (passive and carrier-mediated) of CPT
across the intestinal barrier model. The concentration
dependence was evaluated by investigating the BL to AP
(secretory) transport of CPT at concentrations ranging
from 0.2 µM to 100 µM. The effect of decreasing tempera-
tures on the secretory efflux of CPT was investigated at 4,
10, 15, 25 and 37°C. To delineate the multiple mecha-
nisms involved in the efflux of CPT, permeability was
measured in Caco-2 cells in the presence of the mixed
mechanism efflux inhibitor (etoposide) and the PGP and
BCRP inhibitor (GF120918). Efflux of CPT was studied at
various substrate concentrations (0.2–1.0 µM) and at two
fixed etoposide concentrations (100 and 200 µM).
To further elucidate the possible involvement of other
transporters in the efflux of CPT, studies were conducted
across MDCK II cells transfected with the MDR1 or MRP2
genes. Transport of CPT was evaluated across MDCK II/
PGP cells and MDCK II/MRP2 cells in the presence of the
PGP and BCRP inhibitor GF120918 (0.2 µM) and of the
MRP family inhibitor MK571 (200 µM), respectively.
Control studies were performed in MDCKII/wt cells to
account for passive transport and transport by means of
endogenous (i.e. canine) transporters.
The effective permeability, Peff (cm/s) was determined
using the equation: Peff = (Vr / A x Co) x dC / dt, where Vr
is the volume of the receptor chamber, A is the surface
area of the filter, Co is the initial drug concentration, and
dC/dt is the linear slope of the drug concentration in the
receptor chamber versus the time after correcting for dilu-
tion. Using nonlinear regression software (Scientist ver-
sion 2.01; Micromath, Salt Lake City, UT, USA), the
Michaelis–Menten kinetic values were determined using
the equation: Peff = Pc / (1 + C / Km) + Pm, where Pc is the
carrier permeability (= Jmax / Km), Km is the Michaelis–BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/16
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Menten constant, and Pm is the nonsaturable passive dif-
fusion permeability.
The energy dependence of the efflux transport process for
CPT was determined by calculating the apparent activa-
tion energy (Ea) from an Arrhenius plot (log Peff versus 1 /
T, where T is the absolute temperature [T°C + 273.16°C]
and  R  is the gas constant [0.001987 kcal/deg mole]),
using the equation: slope = -Ea / 2.303R.
A Lineweaver–Burk plot (reciprocal of flux [1 / Peff x C]
versus reciprocal of substrate concentration [1 / C]) was
constructed to determine the type of inhibition observed
when CPT was co-incubated with the efflux transport
inhibitor, etoposide. The inhibition constant (Ki) was
determined from a secondary plot of the slope of the
Lineweaver–Burk plots versus the corresponding inhibitor
concentrations. The intersection of the least-square linear
regression line with the x axis yields the Ki value. To con-
firm the type of inhibition, Eadie–Hofstee plots were also
constructed. Statistical tests were performed using Jandel
Sigma Stat version 2.0 (Jandel Scientific Corp. San Rap-
hael, CA, USA) with a minimum P value of 0.05. One-way
analysis of variance and Tukey tests were performed on
the permeability data. All data are reported as the mean ±
standard deviation unless otherwise noted. Weighted
nonlinear regression was performed using Scientist ver-
sion 2.01 with a weighting factor of 1 / standard
deviation.
Validation of the transfected cell lines by regular confir-
mation of the expression levels is imperative as the trans-
fection may not be complete or the cells may lose
expression over time or with passaging. Immunoblotting
was used to confirm the presence of the transporters of
interest in the MDCK II engineered cell lines. Expression
of PGP and MRP2 in MDCK II cells was confirmed using
western blot analysis. MDCK II/PGP cells, MDCK II/
MRP1 cells and MDCK II/MRP2 cells were harvested after
culturing for 4 days and were lysed in lysis buffer. Ten
micrograms of protein were size fractionated in a polyacr-
ylamide gel containing 7% SDS and were transferred to a
nitrocellulose membrane. The blots were incubated with
antibodies to PGP (C219) and MRP2 (MRP2 H-17), and
were subsequently incubated with anti-mouse or anti-
goat immunoglobulin, respectively. PGP and MRP2 were
detected using an enhanced chemiluminescence system
(Amersham, Downers Grove, IL, USA). PGP and MRP2
transporter protein was also confirmed in MDCK II cells
using western and Slot blots, and was previously pub-
lished by our group [17].
Results
Concentration dependence of CPT absorptive and 
secretory permeability across Caco-2 cells
To determine the apparent transport kinetics of CPT, BL to
AP transport and AP to BL transport of CPT was investi-
gated at concentrations ranging from 0.2 to 100 µM. The
absorptive and secretory permeabilities of CPT were
found to be concentration dependent, with the secretory
Peff (BL–AP) of CPT decreasing from 2.6 × 10-5 to 1.3 × 10-
5 cm/s while the absorptive Peff of CPT decreased from 8.5
× 10-5 cm/s to 3.6 × 10-5 cm/s with increasing drug concen-
trations (Fig. 1a). Complete saturation of the transporters
was not achieved at the highest concentration of CPT
studied due to the limited aqueous solubility of the drug.
However, it was possible to estimate the passive mem-
brane permeability for CPT (secretory passive membrane
permeability, Pm = ~3.5 × 10-6 cm/s; absorptive influx, Pm
= 4.3 × 10-6 cm/s) by conducting the study at low temper-
ature (4°C) since the active transport of drugs across cells
is minimized at low temperatures [18].
Km and Pc for CPT secretory efflux were estimated to be
132.9 ± 12.2 µM and 2.1 ± 0.1 × 10-5 cm/s, respectively,
using weighted nonlinear regression and the aforemen-
tioned equation for the Michaelis-Menten parameters.
These values indicate a low-affinity, high-capacity intesti-
nal efflux transport system for CPT. Similarly, the Km and
Pc values for CPT absorptive transport were estimated to
be 6.9 ± 0.4 µM and 31.2 ± 6.9 µM respectively (Table 1).
The absorptive transport (AP–BL) of CPT across Caco-2
cells was concentration dependent and was significantly
higher than secretory transport, suggesting the presence of
a dominating absorptive transporter located on either the
BL or AP domains or both. Although the investigation of
the absorptive transport of CPT was the focus of our ear-
lier investigation [19], this may have to be re-examined
given the recently described role of MRP1 in the absorp-
tive transport of other drugs [17].
To determine whether CPT efflux was an active (i.e. energy
dependent) process and to estimate the passive permea-
bility component, the BL to AP transport was investigated
at various temperatures ranging from 4°C to 37°C. It was
observed that the efflux Peff of CPT decreased as the tem-
perature was reduced. The energy of activation (Ea) was
estimated to be ~11.3 kcal/mole from the Arrhenius plot
(Fig. 2). Since activation energies greater than 4 kcal/mole
are suggestive of active membrane transport [20], the
secretory permeability of CPT appears to occur by an
active and energy-dependent mechanism.
Inhibition of CPT efflux across Caco-2 cells
The concentration and temperature dependency studies
suggest that active transporters possibly mediate the efflux
of CPT. To confirm this hypothesis, BL to AP transport ofBMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/16
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Concentration dependence of 20-(S)-camptothecin transport across Caco-2 cells (a), MDCK II/wild type (b), MDCK II/P-glyc- oprotein (c) and MDCK II/Multidrug Resistance Protein 2 (d) for apical (AP) to bisolateral (BL) transport (•) and BL to AP  transport (O) Figure 1
Concentration dependence of 20-(S)-camptothecin transport across Caco-2 cells (a), MDCK II/wild type (b), MDCK II/P-glyc-
oprotein (c) and MDCK II/Multidrug Resistance Protein 2 (d) for apical (AP) to bisolateral (BL) transport (•) and BL to AP 
transport (O). Plot of effective permeability (Peff) (mean ± standard deviation) and the best-fit line versus logarithmic concen-
tration. Each point represents the mean (± standard deviation) for at least three observations. Michaelis–Menten parameters 
were determined using a weighted (1 / standard deviation) nonlinear regression and are presented in Table 1.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/16
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CPT was investigated in the presence of etoposide, a
mixed mechanism efflux inhibitor, and GF120918, a spe-
cific PGP and BCRP inhibitor (Fig. 3). Co-incubation of
etoposide with CPT reduced the efflux permeability by
1.3-fold (200 µM), while in the presence of GF120918
(0.4 µM) the CPT efflux was reduced by 2.1-fold. It has
been reported that GF120918 fully reverses PGP-medi-
ated multidrug resistance at concentrations ranging from
0.05 µM to 0.1 µM [21]. However, in the presence of
increasing concentrations of GF120918 (0.8–1.2 µM, data
not shown), where PGP activity is expected to be fully
reversed, the efflux of CPT was not further reduced. This
suggests that other transporters may also be involved in
the transport of CPT.
The efflux inhibition kinetics of CPT were determined by
investigating the BL to AP permeability of CPT at various
substrate and inhibitor concentrations. For etoposide,
concentrations ranging from 100 µM to 200 µM were
selected as the Km value of etoposide was estimated to be
~213 µM in our laboratory [22]. The Km values of CPT in
the presence of increasing concentrations of etoposide
were determined from the Lineweaver–Burk plot (Km =
slope / intercept) (Fig. 4a). In the absence of etoposide,
Table 1: Absorptive (apical to bisolateral) Michaelis–Menten constant (Km), carrier permeability (Pc) and passive permeability (Pm) for 
the transport of 20-(S)-camptothecin (CPT) across Caco-2 cells, MDCK II/wild type (wt) cells, MDCK II/P-glycoprotein (PGP) cells and 
MDCK II/Multidrug Resistance Protein 2 (MRP2) cells
Apical to bisolateral
Caco-2 MDCK II/wt MDCK II/PGP MDCK II/MRP2
Km (µM) 70.1 ± 8.8 71.5 ± 9.7 69.7 ± 7.6 101.2 ± 17.8
Pc (cm/s × 105) 8.3 ± 0.3 2.5 ± 0.7 2.2 ± 0.5 2.5 ± 0.4
Pm (cm/s × 105) 0.43 ± 0.05a Not determined Not determined Not determined
Results reported as the mean ± standard deviation. a Pm was estimated as the efflux Peff of CPT at 4°C.
Temperature dependence of 20-(S)-camptothecin transport  across Caco-2 cells for basolateral to apical transport Figure 2
Temperature dependence of 20-(S)-camptothecin transport 
across Caco-2 cells for basolateral to apical transport. Plot of 
logarithmic effective permeability (Peff) (mean ± standard 
deviation) and the best-fit line versus the reciprocal of abso-
lute temperature. Each point represents the mean (± stand-
ard deviation) for at least three observations. The activation 
energy (Ea), was determined based on the equation: slope = -
Ea / 2.303R, where R is the gas constant (= 0.001987 kcal/deg 
mole).
Inhibition of 20-(S)-camptothecin (10 µM) efflux transport  across Caco-2 cells Figure 3
Inhibition of 20-(S)-camptothecin (10 µM) efflux transport 
across Caco-2 cells. Each point represents the mean (± 
standard deviation) for at least three observations. * Efflux 
permeability (with inhibitor) is significantly different from the 
control (without inhibitor), P < 0.05. Peff, effective 
permeability.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/16
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Lineweaver–Burk plot (a) and Eadie–Hofstee plot (b) of inhibition of 20-(S)-camptothecin efflux across Caco-2 cells at fixed  etoposide concentrations of 0 µM (∆), 100 µM (•) and 200 µM () Figure 4
Lineweaver–Burk plot (a) and Eadie–Hofstee plot (b) of inhibition of 20-(S)-camptothecin efflux across Caco-2 cells at fixed 
etoposide concentrations of 0 µM (∆), 100 µM (•) and 200 µM (). Each point represents the mean (± standard deviation) for 
at least three observations. The inhibition constant (Ki) was determined from a secondary plot (inset) of the slopes of 
Lineweaver–Burk plots for various inhibitor concentrations. Peff, effective permeability; V0, initial rate.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/16
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the Km value of CPT was 173.2 µM using the Lineweaver–
Burk plot, which is different from that obtained using
nonlinear regression (132 µM). The use of linearization
techniques to analyze nonlinear data is well known to
introduce error into the parameter (Km, Vmax, Jmax) esti-
mates. The linearization techniques were therefore only
used in a qualitative manner to show the kinetic behavior
of the inhibitors with CPT.
To further confirm the type of inhibition, Eadie–Hofstee
plots were also constructed (Fig. 4b). The Km values of CPT
in the presence of etoposide were also found to be differ-
ent from those obtained using nonlinear regression. This
further demonstrates that linearization of the data can
result in inconsistencies, making it difficult to conclu-
sively determine the type of inhibition. The inhibition
constant Ki was obtained from the intercept of the double-
reciprocal of the Lineweaver–Burk plot (Fig. 4a, inset).
The inhibition of CPT secretory efflux by etoposide was
found to be weak (Ki = 1044.2 ± 73.1 µM); however, con-
firmation of the earlier Ki value using nonlinear regression
was not possible due to the complex nature of the inhibi-
tion and the unreliability of the estimates. These results
confirm that etoposide is a mixed mechanism inhibitor
and the inhibition is possibly due to interactions of vari-
ous types with multiple transporters.
Concentration dependence of CPT transport across 
transfected and wt MDCK II cells
The absorptive and secretory transport of CPT across
MDCK II/wt cells was found to be concentration depend-
ent, with the absorptive Peff of CPT decreasing from 2.7 ×
10-5 to 1.1 × 10-5 cm/s while the efflux Peff decreased from
2.2 × 10-5 to 1.0 × 10-5 cm/s at concentrations ranging
from 0.5 to 100 µM (Fig. 1b). Complete saturation of the
transporters was not attained at the highest concentration
of CPT used (100 µM) due to solubility limitations. In
MDCK II/PGP cells and MDCK II/MRP2 cells, transport of
CPT was concentration dependent (0.5–100 µM) in both
the AP to BL and the BL to AP directions (Fig. 1c,1d). The
secretory Peff of CPT decreased from 4.7 × 10-5 to 2.0 × 10-
5 cm/s across MDCK II/PGP cells and from 4.5 × 10-5 to
1.4 × 10-5 cm/s across MDCK II/MRP2 cells, and it was
approximately twofold greater than that observed across
MDCKII/wt cells (Table 2).
The efflux ratio of permeabilities (BL–AP/AP–BL) of CPT
in MDCK II/wt cells was approximately 1 while the ratios
in MDCK II/PGP cells and MDCK II/MRP2 cells were
greater than 1, confirming that the transfected gene prod-
ucts dominated the transport behavior as compared with
the endogenous canine transporters. These results
correlate well with the increased expression levels of PGP
and MRP2 in MDCK II/PGP and MDCK II/MRP2 cells,
respectively, relative to MDCK II/wt cells (Fig. 5) and sug-
gest that these transporters are possibly involved in the
secretory efflux of CPT.
Inhibition of CPT secretory permeability across MDCK II 
cells
To determine the extent to which PGP and MRP2 are
involved in the efflux of CPT, CPT transport was investi-
gated in the presence of GF120918, a specific PGP and
BCRP inhibitor, and in the presence of MK571, a potent
MRP family inhibitor, using MDCK II/PGP cells and
MDCK II/MRP2 cells, respectively. In the presence of
GF120918 (0.2 µM) the absorptive transport of CPT
across MDCK II/PGP cells increased by ~52% while efflux
decreased by 31% (Fig. 6a). The incomplete reversal of the
efflux ratio (3.36 to 1.49) implies that either PGP was not
completely inhibited by GF120918 at the dose investi-
gated or that another transporter may be present and play
a role in the efflux of CPT.
In MDCK II/MRP2 cells, the absorptive transport of CPT
increased by ~33% while secretory permeability decreased
by ~35% in the presence of MK571 (200 µM) (Fig. 6b).
The efflux ratio was completely reversed (2.31 to 1.03),
suggesting that MK571 completely inhibited MRP2.
These results further confirmed the involvement of PGP
and MRP2 in the efflux of CPT.
Table 2: Secretory (bisolateral to apical) Michaelis-Menten constant (Km), carrier permeability (Pc) and passive permeability (Pm) for 
transport of 20-(S)-camptothecin (CPT) across Caco-2 cells, MDCK II/wild type (wt) cells, MDCK II/P-glycoprotein (PGP) cells and 
MDCK II/Multidrug Resistance Protein 2 (MRP2) cells
Bisolateral to apical
Caco-2 MDCK II/wt MDCK II/PGP MDCK II/MRP2
Km (µM) 132.9 ± 12.2 81.3 ± 14.6 36.3 ± 7.5 65.8 ± 6.7
Pc (cm/s × 105) 2.1 ± 0.1 2.0 ± 0.2 4.1 ± 0.4 4.3 ± 0.7
Pm (cm/s × 105) 0.35 ± 0.04a Not determined Not determined Not determined
Results reported as the mean ± standard deviation. a Pm was estimated as the efflux Peff of CPT at 4°C.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/16
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Discussion
Clinical resistance to chemotherapeutic drugs is a major
obstacle in the treatment of cancer. The ATP-binding
cassette (ABC) family of membrane transporters has been
strongly implicated in the development of resistance, and
numerous studies have been conducted in an attempt to
identify structural specifications for these transporters.
The roles of these transporters in limiting the absorption
and disposition of drugs, however, have not been exten-
sively studied. In the present study we investigated the
role of two of the ABC transporters involved in multidrug
resistance (MDR), namely PGP and the multidrug
resistance associated protein 2 (MRP2/cMOAT), on the
absorptive and secretory permeability of CPT. The roles of
MRP1, MRP3 and BCRP on the permeability of CPT were
not specifically addressed in this study. However, ongoing
studies in our laboratory are evaluating the potential role
of these transporters on the absorption and disposition of
the CPTs.
Since our initial goal was to elucidate the roles of mem-
brane transporters in the absorption of CPT, we use
'absorptive' to indicate net transport in the AP to BL
direction and we use 'secretory' to indicate net BL to AP
transport. The absorptive and secretory permeabilities of
CPT were initially evaluated in Caco-2 cells, a well-charac-
terized model for studying the intestinal transport of
drugs. Given the multiplicity of membrane transporters in
Caco-2 cells and the lack of specific transport inhibitors,
the overall mechanistic value of the Caco-2 results is ques-
tioned. However, given the wide use of Caco-2 cells as a
Overexpression of P-glycoprotein (PGP) and Multidrug  Resistance Protein 2 (MRP2) in MDCK II cells using western  blot analysis Figure 5
Overexpression of P-glycoprotein (PGP) and Multidrug 
Resistance Protein 2 (MRP2) in MDCK II cells using western 
blot analysis. Ten milligrams of protein of each cell lysate 
were size fractionated in a polyacrylamide gel containing SDS. 
Blots of the gel were incubated with antibodies to PGP 
(C219) and MRP2 (MRP2 H-17), followed by enzyme-linked 
anti-mouse or anti-goat antibodies, respectively. The images 
were then developed by enhanced chemiluminescence.
MDCK II/wt
MDCK II/MRP1
MDCK II/P-gp
MDCK II/MRP2
MRP2
P-gp
β-Actin
MDCK II/wt
MDCK II/MRP1
MDCK II/P-gp
MDCK II/MRP2
MDCK II/wt
MDCK II/MRP1
MDCK II/P-gp
MDCK II/MRP2
MRP2
P-gp
β-Actin
Inhibition of 20-(S)-camptothecin efflux transport across  MDCK II/P-glycoprotein (PGP) cells in the presence of  GF120918 (0.2 µM) (a), and across MDCK II/Multidrug  Resistance Protein 2 (MRP2) cells in the presence of MK571  (200 µM) (b) Figure 6
Inhibition of 20-(S)-camptothecin efflux transport across 
MDCK II/P-glycoprotein (PGP) cells in the presence of 
GF120918 (0.2 µM) (a), and across MDCK II/Multidrug 
Resistance Protein 2 (MRP2) cells in the presence of MK571 
(200 µM) (b). Each point represents the mean (± standard 
deviation) for at least three observations. * Efflux permeabil-
ity (with inhibitor) is significantly different from the control 
(without inhibitor), P < 0.05. AP, apical; BL, bisolateral, Peff, 
effective permeability.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/16
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standard for assessing the absorption potential of drugs,
the current results are a valuable addition to that ever
growing database. In addition, the Caco-2 results
provided a rationale for further mechanistic studies using
the MDCK II cell lines.
Numerous transporters have been implicated in the efflux
of the camptothecin analogs (CPT-11 and TPT), including
PGP [23], MRP2 [24], MRP1 and BCRP [16] from cells.
These transporters are overexpressed in tumor cell lines,
displaying cross-resistance to a broad range of structurally
and functionally unrelated drugs [25]. BCRP, PGP, and
MRP2 are apically localized on the epithelial cells in nor-
mal tissues, such as the intestine, kidney and liver, where
they are believed to mediate drug secretion and efflux in
the intestine and liver, possibly influencing net absorp-
tion and body and cellular disposition. In comparison
with PGP, the role of MRP2 on drug pharmacokinetic pro-
files is not as well characterized. The transport of CPT was
therefore evaluated across MDCK II cells transfected with
the MDR and MRP2 genes.
The absorptive Pc of CPT across MDCK II/wt cells, MDCK
II/PGP cells and MDCK II/MRP2 cells was found to be
similar, possibly due to the presence of endogenous
MRP1 located on the basolateral membrane and the lack
of specialized influx transporters on the AP domain. In
Caco-2 cells, however, the absorptive permeability (AP–
BL) of CPT was significantly higher, suggesting the possi-
ble involvement of an absorptive transporter for CPT. It is
also possible that the results could be explained by differ-
ences in the types of transporters expressed or expression
levels. For example, one possible mechanism may be that
a higher level of MRP1 activity in Caco-2 cells led to
enhanced CPT efflux in the absorptive direction. These
results also imply that passive diffusion may not be solely
responsible for the absorption of CPT.
The secretory permeability of CPT was comparable in
Caco-2 cells and in MDCK II/wt cells; however, it was
approximately twofold greater (Table 1) in MDCK II/PGP
cells and MDCK II/MRP2 cells. This result clearly impli-
cates endogenous transporters in the secretion of CPT
from MDCK II/wt cells. It is difficult to assess which
endogenous transporters may be involved, but recent
work in our laboratory using these cell lines demonstrates
the presence and activity of endogenous canine PGP,
MRP1, and MRP2 [17]. Since the efflux ratio of CPT was
greater than 1 in MDCKII cells overexpressing PGP and
MRP2, compared with MDCKII wt cells, the current
results show that the overexpressed human transporters
had a higher activity than the endogenous transporters,
and an adequate signal to noise ratio was achieved allow-
ing us to discern transport relationships for CPT with PGP
and MRP2. The Km  value was approximately twofold
lower across MDCK II/PGP cells than across MDCK II/
MRP2 cells, indicating that CPT has a higher affinity for
the PGP transporter. This is consistent with a previous
report that suggests that PGP and MRP2 are likely to be
the high-affinity and low-affinity transporters, respec-
tively, for CPT and its analog CPT-11 [23].
MDCKII cells are derived from the dog kidney while Caco-
2 cells are of human colonic origin. These differences in
species and organ location of origin could imply poten-
tially large differences in the type and activity of transport-
ers in each cell line. On a macroscopic level, on the other
hand, the secretory permeability of CPT was found to be
similar in Caco-2 cells and in MDCK II/wt cells (Table 2).
This suggests that MDCK II/wt cells could be an attractive
alternative cell model to Caco-2 cells for studying drug
transport, especially since the culturing time for MDCK
cells is only 3 days compared with the 21-day standard for
Caco-2 cells.
Most of the studies to date investigating the multidrug
resistance phenomenon have been conducted in cancer
cells. Cellular accumulation of CPT-11, SN-38 and TPT in
tumor cells overexpressing the PGP transporter was found
to be reduced [26], and this reduction in cellular accumu-
lation was reversed by PGP reversal agents [26-28]. How-
ever, conflicting reports have been published on the
affinity of CPT for PGP [29-31]. The presence of a positive
charge at physiological pH is thought to be necessary for
binding to PGP. However, differing susceptibility of TPT,
CPT-11 and 9-aminocamptothecin to PGP-mediated
MDR and the much lower resistance levels compared with
typical MDR compounds suggests that the positive charge
is probably not an absolute requirement for PGP binding.
In addition, these discrepancies could result from the use
of cells selected for drug resistance that overexpress
multiple transporters, or cell surrogates of normal human
enterocytes such as Caco-2 that contain a wide variety of
transporters and metabolizing enzymes. In these systems
the role of specific transporters and the interpretation of
kinetic data is difficult as multiple known or unknown
transporters are present. The use of cell surrogates for
studying drug transport in vitro therefore presents a chal-
lenge. This can be overcome using cells engineered to
overexpress certain membrane transporters, as demon-
strated in this study.
Evaluating the transport of a drug in the presence of spe-
cific inhibitors can provide useful information on the role
of various transporters on drug permeability. In the pres-
ence of the mixed mechanism efflux inhibitor etoposide,
the secretory permeability of CPT was only weakly inhib-
ited (apparent Ki = 1040 ± 131 µM). Etoposide interacts
with numerous transporters (i.e. mixed mechanism), and
the nature of each interaction (i.e. competitive,BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/16
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uncompetitive or noncompetitive) has not been thor-
oughly studied. Even though the large apparent Km/low
affinity reflects the possible interactions with numerous
transporters, complete inhibition was observed. The
apparent discrepancy between the Eadie–Hofstee and
Lineweaver–Burk plots in characterizing the type of inhi-
bition by etoposide is also a reflection of the possible and
different types of interactions with multiple known and
unknown transporters. For this reason, we chose to use
cell lines that overexpress transporters of interest, PGP
and MRP2, in order to increase the sensitivity of the cell
model to a specific transporter interaction.
The absorptive transport of CPT across MDCK II/PGP cells
increased while the secretory transport decreased in the
presence of GF120918. Similarly, in MDCK II/MRP2 cells
the absorptive transport of CPT increased, while efflux
decreased in the presence of MK571. Although the results
are qualitatively similar, the mechanisms are probably
very different. For example, since PGP/BCRP are apically
located, inhibition of AP efflux would be expected to
increase the total AP to BL permeability while decreasing
the BL to AP flux. On the other hand, the net effect of
inhibiting MRP1, MRP2 and, possibly, MRP3 is less pre-
dictable since they are all efflux transporters, but MRP1 is
oriented as an absorptive transporter while MRP2 and
MRP3 are oriented as secretory transporters. One possible
scenario is that MK571 more strongly inhibited MRP2/
MRP3 than MRP1, facilitating an increase in AP to BL per-
meability. However, without further mechanistic studies
and highly specific inhibitors it is not possible to show
this conclusively.
Due to the narrow therapeutic index for the camp-
tothecins and the requirement for constant blood levels,
low bioavailability and interpatient variability limits the
viability of the oral delivery route. Although approved for
parenteral use, none of the CPTs have yet received
approval for oral administration. The metabolism of CPT
has been evaluated in our laboratory by incubating the
drug with rat intestinal and liver s9 fractions and micro-
somes. Minimal degradation of CPT was observed, sug-
gesting that the first-pass metabolism is unlikely to
contribute significantly to the variable bioavailability of
CPT (data not shown). Elimination of CPT occurs through
the biliary and urinary routes [13], and therefore the pres-
ence of PGP and MRP2 in the liver and kidney may also
affect the oral bioavailability and disposition of CPT. The
current results suggest that the intestinal absorption and
disposition of CPT is probably mediated by several active
transporters, and we specifically demonstrate the involve-
ment of PGP and MRP2 in the efflux of CPT. This may
contribute in part to the variable oral absorption of CPT
[9] since the absorption of CPT occurs primarily from the
ileum, which has significant drug secretion capacity com-
pared with other regions of the gastrointestinal tract [32].
Conclusions
An appreciation of the role of transporters on the absorp-
tion and secretion of drugs is critical in understanding the
poor and erratic bioavailability observed when the oral
route is utilized for drug administration. The extent to
which intestinal absorption and secretion contributes to
the erratic bioavailability of CPT is currently unknown.
The present study was therefore conducted to elucidate
the role of two of the ABC transporters involved in MDR,
namely PGP and the multidrug resistance associated pro-
tein 2 (MRP2/cMOAT), on the absorption of CPT. The
study provides experimental evidence demonstrating that
the in vitro secretion of CPT is mediated by the active
transporters PGP and MRP2. Variation in the expression
levels and activity of PGP and/or MRP2 in the intestine,
liver and kidney may therefore be responsible for the
inconsistent systemic availability of CPT observed in
human subjects after oral administration.
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